Hologic’s HOLX acquisition of Biotheranostics in 2021 accelerated its entry into a large, fast-growing oncology adjacency. The business also carries higher margins than the company’s legacy service ...

Hormones control essential processes like growth, metabolism, mood, and reproduction, but when their balance is disrupted, it ...

bioTheranostics, Inc's Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be ...

I am Jess Bruce Assistant Manager in Transparency Market Research (TMR). TMR is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of ...

New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration Findings from 11 ...

Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. Rate of medical ...

Please provide your email address to receive an email when new articles are posted on . An assessment of free cortisol after a dexamethasone suppression test could add value to the diagnostic workup ...

dvm360: What can [lecture] attendees learn about concurrent endocrine and dermatological disease?

Findings from 11 investigational studies include new data in premenopausal women and comparative analyses of BCI Testing to the 21-gene assay “These data reinforce Hologic’s continued commitment to ...